

**Disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

**Part-A- Details of the Acquisition**

Name of the Target Company (“TC”)	Thyrocare Technologies Limited		
Name(s) of the acquirer and Persons Acting in Concert (“PAC”) with the acquirer	<b>Acquirer:</b> Docon Technologies Private Limited  <b>PAC:</b> API Holdings Private Limited		
Whether the acquirer belongs to Promoter/Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited  National Stock Exchange of India Limited		
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
<b>Before the acquisition under consideration, holding of acquirer along with PACs of:</b>			
a) Shares carrying voting rights	0	0.00%	0.00%
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	0	0%	0%
c) Voting rights (“VR”) otherwise than by equity shares	0	0%	0%
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	0	0%	0%
e) Total (a+b+c+d)	0	0.00%	0.00%
<b>Details of acquisition</b>			
a) Shares carrying voting rights acquired	26,83,093	5.07%	5.07%
b) VRs acquired otherwise than by equity shares	0	0%	0%

c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying category) acquired	0	0%	0%
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	0	0%	0%
e) Total (a+b+c+/-d)	26,83,093	5.07%	5.07%
<b>After the acquisition, holding of acquirer along with PACs of:</b>			
a) Shares carrying voting rights	26,83,093	5.07%	5.07%
b) VRs otherwise than by equity shares	0	0%	0%
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	0	0%	0%
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	0	0%	0%
e) Total (a+b+c+d)	26,83,093	5.07%	5.07%
Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer/encumbrance, etc.)	Acquisition of equity shares validly tendered in the open offer.		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	Equity shares carrying voting rights		
Date of acquisition of/ date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	25 August 2021		
Equity share capital / total voting capital of the TC before the said acquisition	5,28,74,419 equity shares of the TC (as per the shareholding pattern as on 30 June 2021 as publicly disclosed by the TC)		
Equity share capital/ total voting capital of the TC after the said acquisition	5,28,74,419 equity shares of the TC (as per the shareholding pattern as on 30 June 2021 as publicly disclosed by the TC)		
Total diluted share/voting capital of the TC after the said acquisition	5,28,74,419 equity shares of the TC (as per the shareholding pattern as on 30 June 2021 as publicly disclosed by the TC)		

**Part-B\*\*\***

**Name of the Target Company:** Thyrocare Technologies Limited

Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Whether the acquirer belongs to Promoter/ Promoter group	PAN of the acquirer and/or PACs
<b>Acquirer:</b> Docon Technologies Private Limited	No	
<b>PAC:</b> API Holdings Private Limited	No	

**Note:**

(\*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(\*\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(\*\*\*) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

For and on behalf of Docon Technologies )  
Private Limited )

)  
)  
)  
)  
)  
)




---

**Authorised Signatory**  
Name: Hardik Dedhia  
Designation: Director  
Date: 26 August, 2021  
Place: Mumbai

**For and on behalf of API Holdings Private )  
Limited**

)  
)  
)  
)  
)  
)



---

**Authorised Signatory**  
Name: Harsh Parekh  
Designation: Whole-time Director  
Date: 26 August, 2021  
Place: Mumbai